Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

BACKGROUND: Patients with advanced squamous-cell non–small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully h...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :N Engl J Med
Главные авторы: Brahmer, Julie, Reckamp, Karen L., Baas, Paul, Crinò, Lucio, Eberhardt, Wilfried E.E., Poddubskaya, Elena, Antonia, Scott, Pluzanski, Adam, Vokes, Everett E., Holgado, Esther, Waterhouse, David, Ready, Neal, Gainor, Justin, Frontera, Osvaldo Arén, Havel, Libor, Steins, Martin, Garassino, Marina C., Aerts, Joachim G., Domine, Manuel, Paz-Ares, Luis, Reck, Martin, Baudelet, Christine, Harbison, Christopher T., Lestini, Brian, Spigel, David R.
Формат: Artigo
Язык:Inglês
Опубликовано: 2015
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4681400/
https://ncbi.nlm.nih.gov/pubmed/26028407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1504627
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы